Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.
FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC
Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV
FDA Approves Noninvasive Stool RNA Screening Test for CRC
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer
Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer